Glenmark Pharma leads the gainers of ‘BSE Health Care’ space

11 Aug 2011 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 328.20, up by 9.10 points or 2.85% from its previous closing of Rs. 319.10 on the BSE.

The scrip opened at Rs. 324.40 and has touched a high and low of Rs. 330.90 and Rs. 323.50 respectively. So far 4,246 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 389.75 on 07-Dec-2010 and a 52 week low of Rs. 241.60 on 28-Feb-2011.

Last one week high and low of the scrip stood at Rs. 330.90 and Rs. 301.20 respectively. The current market cap of the company is Rs. 8872.00 crore.

The promoters holding in the company stood at 48.30% while Institutions and Non-Institutions held 38.09% and 13.60% respectively.

Glenmark Pharmaceuticals’ novel chemical entity “Revamilast” has initiated  Phase II B human dose range  finding trial globally. Revamilast is an orally active, potent and selective inhibitor  of phosphodiesterase 4 (PDE 4) that is  currently being developed  by Glenmark for the treatment of chronic  inflammatory disorders such as  Asthma, Rheumatoid Arthritis (RA)  and other inflammatory diseases.

The Phase II studies going to be carried out will help establish the efficacy and safety of the molecule and will also provide dose range finding data for Revamilast.

Glenmark Pharmaceuticals is research driven globally integrated pharmaceuticals company headquartered in Mumbai. It is leading player in the discovery of new molecules both NCEs (New chemical entity) and NBEs (New biological entity).

Glenmark Pharma Share Price

1976.35 2.20 (0.11%)
05-Dec-2025 14:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.90
Dr. Reddys Lab 1275.00
Cipla 1523.20
Zydus Lifesciences 933.20
Lupin 2104.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×